A Phase II Trial for Mefatinib (MET-306) in the treatment of EGFR rare mutations (g719x, l861q, s768i) in Patients with advanced non-small cell lung cancer
Latest Information Update: 12 Jul 2022
At a glance
- Drugs Mefatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2022 Status changed from recruiting to completed, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Mar 2021 New trial record